SAGE THERAPEUTICS INC's ticker is SAGE and the CUSIP is 78667J108. A total of 220 filers reported holding SAGE THERAPEUTICS INC in Q2 2020. The put-call ratio across all filers is 0.84 and the average weighting 0.2%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2021 | $559,000 | -87.7% | 12,608 | -84.2% | 0.00% | -89.3% |
Q2 2021 | $4,528,000 | -0.8% | 79,708 | +30.7% | 0.03% | -6.7% |
Q1 2021 | $4,566,000 | +2408.8% | 61,008 | +2805.1% | 0.03% | +2900.0% |
Q4 2020 | $182,000 | -33.6% | 2,100 | -68.2% | 0.00% | -50.0% |
Q2 2020 | $274,000 | – | 6,600 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
DAFNA Capital Management LLC | 99,306 | $14,027,000 | 5.76% |
Casdin Capital, LLC | 312,000 | $44,070,000 | 5.36% |
Palo Alto Investors LP | 840,372 | $118,703,000 | 4.80% |
BB BIOTECH AG | 1,071,373 | $151,331,000 | 4.00% |
TRV GP II, LLC | 37,362 | $5,277,000 | 3.10% |
Eversept Partners, LP | 43,621 | $6,161,466 | 2.70% |
RA Capital Management | 350,933 | $49,569,000 | 2.65% |
Eventide Asset Management | 494,000 | $69,778,000 | 2.56% |
OAK RIDGE INVESTMENTS LLC | 241,099 | $34,055,000 | 1.88% |
SUFFOLK CAPITAL MANAGEMENT LLC | 93,000 | $13,136,000 | 1.87% |